The diagnostic performance of CA125, HE4 and other candidate biomarkers on the panel markedly reduced with increasing lag-time between blood draw and cancer diagnosis, which is in line with previous studies [3, 4, 25], and is to be expected for markers genuinely associated with tumour development. The gene discussed is MUC16; the disease is neoplasm.